Lloyd Klickstein, M.D., Ph.D., has served on Adicet Bio's board since August 2024. Since April 2024 he has been president and CEO of Koslapp Therapeutics.
He was founding CEO and subsequently president and chief scientific officer of Versanis Bio, and previously served as Adicet's Chief Innovation Officer and, before that, as Chief Scientific Officer of resTORbio. Earlier he was Head of Translational Medicine for the New Indication Discovery Unit and Exploratory Disease Area at Novartis Institutes for Biomedical Research. He received his B.S. from Tufts University and his M.D. and Ph.D. from Harvard University.